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INTRODUCTION
Fibromyalgia (FM), also known as fibromyalgiasyndrome (FMS), is a frequently observed sys-
temic disorder characterized by widespread muscu-
loskeletal pain (1, 2). Its prevalence in the general
population is 1-3%, and it is more common among
females than males. The American College of
Rheumatology (ACR) classification criteria defines
it as widespread pain with patients endorsing at least
11 of 18 tender points as painful (3). Although its
defining feature is chronic, widespread pain, FM pa-
tients may also have a number of other symptoms
including sleep disturbance, fatigue, irritable bowel
syndrome, headache and mood disorders (1). 
Current evidence advocates a multifaceted program
emphasizing patient education, medications for im-
RIASSUNTO
Il trattamento farmacologico della sindrome fibromialgica (FM) si è gradualmente arricchito di nuove molecole; tut-
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proving symptoms, and aggressive use of exercise
and cognitive-behavioural approaches to retain or
restore function (4-6). Physicians and patients
should be educated about current theories regard-
ing the underlying pathophysiologic mechanisms
of FM, and then set realistic goals for all modali-
ties of treatment. 
However, it is not possible to draw definite con-
clusions concerning the best approach to managing
FM because results of randomized clinical trials
present methodological limitations, and therapeu-
tic programs are consistently heterogeneous, which
renders them difficult to compare (7,8). However,
a variety of pharmacological treatments, including
analgesics, antidepressants, antiepileptics and
many other drugs have been used to treat symptoms
of FM with mixed results (8). In this review, we
will discuss those drugs that have produced the
most significant clinical results in treating FM pa-
tients.
Analgesics
The use of steroids and nonsteroidal anti-inflam-
matory drugs (NSAIDs) in FM has had disap-
pointing outcomes (1, 8). NSAIDs, which are com-
monly used for arthritic conditions, may be less ef-
fective for FM because pain associated with FM is
not caused by muscle or joint inflammation. There
is no scientific evidence that NSAIDs are effective
when used alone in FM patients, although they may
be useful adjuncts for analgesia when combined
with tricyclic medications (1); the combination of
NSAIDs with benzodiazepines, however, gave in-
consistent results (1, 7-9). 
The central nervous system (CNS) mechanisms for
the disorder, specifically, central sensitization, cen-
tral disinhibition and a dysfunctional hypothalam-
ic-pituitary-adrenal axis, could justify the relative-
ly reduced efficacy of NSAIDs and opioids, the
latter being more effective for “peripheral” pain
(7). However, NSAIDs can be helpful in reducing
pain that flares with excessive physical activity,
tendinitis or bursitis; but they should be used only
as needed to avoid side effects. COX2 inhibitors
have much fewer side effects, but have less effica-
cy in pain.
Acetaminophen acts differently for FM patients; it
has a degree of strength for FM and is safe for use
over long periods (9). Wolfe et al. surveyed
rheumatic disease patients about their preferences
for NSAIDs versus acetaminophen in terms of ef-
ficacy and side effects (10). There was a consider-
able and statistically significant preference for
NSAIDs among patients; but the authors stress that
if safety and costs are issues, then the recommen-
dation of the American College of Rheumatology
that acetaminophen be the first choice, primarily
for mild pain, seems appropriate given the long du-
ration of safe use (11).
The use of NSAIDs or acetaminophen, with or
without opioids, is always justified when patients
who already suffer from FM have other peripheral
sources of pain (osteoarthritis, inflammatory arthri-
tis, degenerative disk disease) (11).
Opioids are meant to improve function in FM pa-
tients who are impaired by pain, even though there
is an open debate about their usefulness and safe-
ty as a “specific” medication for fibromyalgia pa-
tients (12-14). 
Few clinical trials exist that address the use of opi-
oids to treat persistent pain in FM patients, but
those trials show that these drugs are helpful for re-
lieving FM pain; moreover, opioids can help to re-
duce sleep disturbances, anxiety and depression
and to increase mobility and enjoyment of life (13,
15). 
Potential side effects tend to decline over time, and
addiction has been disproven by the scientific lit-
erature.
Opioids that are available on the Italian market in-
clude codeine, tramadol, oxycodone, hydromor-
phon, morphine, buprenorphine and fentanyl. 
Furlan et al. (15) conducted a meta-analysis of 41
randomized trials (6019 patients, 7% affected by
FM) to evaluate the efficacy of opioids ranging in
duration from 1-16 weeks. They found that opi-
oids were more effective than placebo for both pain
and functional outcomes; and strong opioids were
significantly superior to naproxen and nortripty-
line, but only for pain relief. Despite the relative
brevity of the trials, more than 1/3 of the partici-
pants abandoned treatment (15). 
Tramadol, in particular, was beneficial for FM pa-
tients (8, 9, 12-14). It is an atypical pain reliever
that differs from other narcotics in its action on the
central nervous system, specifically, on reuptake
of serotonin and norepinephrine. Its most common
side effects are drowsiness, dizziness, constipation
and nausea, and it should not be given in combi-
nation with tricyclic antidepressants. 
Tramadol, used alone or in combination with ac-
etaminophen, is commonly prescribed for relief of
fibromyalgia pain (16-18) in a dose of 200-300
mg/d. A small double-blind, placebo-controlled tri-
al initially suggested that tramadol was effective
and well-tolerated in patients with FM (16). 
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A larger RCT (n=69) reported decreased visual
analogue pain scores, improved pain relief and de-
creased pain threshold after tramadol treatment.
Another study compared a combination of 37.5 mg
tramadol/325 mg acetaminophen tablets with
placebo in 315 patients with FM. Pain and physi-
cal functioning improved significantly in the tra-
madol/acetaminophen-treated subjects. The aver-
age dose of tramadol/acetaminophen was 4.0±1.8
tablets per day with an attrition rate of 19% (n=29)
due to adverse events. The attrition rate in the
placebo-treated subjects was 12% (n=18). This
study suggested that the combination of tra-
madol/acetaminophen was effective in treating FM
patients’ pain without causing serious adverse
events (17). 
Bennett et al. (18) examined efficacy data to com-
pare the impact of tramadol/acetaminophen versus
placebo on quality of life; the authors concluded that
moderate-to-severe fibromyalgia pain significantly
impairs health-related quality of life (HRQOL) in
placebo-treated patients.
A recent study has demonstrated that transdermal
buprenorphine, a strong opioid, has beneficial ef-
fects on severe widespread pain (VAS >6/10), but
it is less effective on other symptoms that are typ-
ical of the disease (19).
FM that is diagnosed according to the ACR crite-
ria seems to include patients with different pain
processing mechanisms. Screening for disorders
that may initiate or exacerbate symptoms of FM is
critical; if comorbid disorders are not identified
early and treated appropriately, therapies that tar-
get FM, only, may be ineffective.
In fact, there is a subset of FM patients that do not
respond to opioids, while other patients, who may
have overlapping conditions such as diabetes,
chronic myofascial pain, temporomandibular joint
disorder, arthritis, degenerative disc disease and
other diseases, may benefit quite significantly from
opioids (8, 18).
Physicians should obtain a careful medical and psy-
chological profile of the patient before prescribing
opioids (17, 18). Therapy with these drugs should
be initiated after an adequate trial of aceta-
minophen for nociceptive pain and of tricyclic an-
tidepressants or anticonvulsants. 
To obtain a synergistic effect on analgesia, some
patients may be prescribed combinations of differ-
ent pain relievers (multimodal analgesia) with dif-
ferent effects on pain pathways, but not for man-
aging side effects. Patients should be asked to give
informed consent for treatment; even though it is
not necessary for legal purposes, it would help to
educate patients and give them a sense of respon-
sibility (18).
It is appropriate to increase doses of immediate-re-
lease opioids slowly until pain reduction is
achieved and then switch patients to controlled-re-
lease opioids, considering that most patients with
chronic, non-malignant pain can be managed with
<200-300 mg/d of morphine (or equivalent).
When opioids prove to be necessary, they must, of
course, be used with extreme caution. Patients
should be evaluated periodically for continuing
pain relief, side effects and indications of depen-
dence. They must be closely monitored, must agree
to seek psychotherapy and must complete a signed
agreement to communicate with a single prescrib-
ing physician and a single dispensing pharmacy. 
As with any chronic pain syndromes, patients
should be carefully selected for opioid therapy, and
a plan for appropriate follow-up and monitoring
for pain reduction, outcome improvement, side ef-
fects and misuse should be clearly outlined. The in-
terdiction of all opioid medications is inappropri-
ate because some patients cannot achieve a rea-
sonable quality of life and daily functioning with
any other treatment. 
Harris, et al. (20) have tried to investigate the ap-
parent insensitivity of FM patients to opioids. Us-
ing positron emission tomography (PET), they
found that FM patients, compared to healthy,
matched controls, had reduced µ-opioid-receptor
(MOR)-binding potential (BP) in the nucleus ac-
cumbens, the anterior cingulate and the amygdala.
These areas of the brain are known to play a role
in pain modulation (14). 
These findings indicate altered endogenous opioid
analgesic activity in FM and suggest a possible ex-
planation for the reduced efficacy of exogenous
opioids in this population.
Antidepressants
The treatment of pain requires a multimodal ap-
proach that has to consider not only somatic aspects
(i.e., pain onset, location, quality, quantity, dura-
tion, aggravating and alleviating factors), but also
emotional aspects (i.e., mood and anxiety), cogni-
tive aspects (i.e., coping styles, beliefs about pain),
and environmental aspects (i.e., social context and
patients’ relationships) (1, 2, 8). The hypothesis
that pain, anxiety, chronic stress and depression
share common pathogenetic backgrounds which
are represented by neurotransmitters and immune
response is noteworthy. As such, depression must
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be considered as a systemic disease that is related
not only to neurotransmission imbalance, but also
to other neurotrophic, neurosteroidal, CNS hor-
monal modifications and diffuse, autonomic, im-
munologic, and metabolic somatic changes (8, 21).
According to this hypothesis, antidepressants re-
store neurotransmitter levels and modulate recep-
tor expression in the hypothalamus, which nor-
malizes hyperactivity of the hypothalamic-pitu-
itary-adrenal (HPA) axis (18, 1). An over-activation
of the HPA axis is observed in depression and in
chronic stress, both of which are frequently present
in patients with long-term pain disorders. Con-
versely, the response to stress is considered to play
a crucial role in the pathogenesis of several syn-
dromes, such as FM, chronic fatigue syndrome and
irritable bowel syndrome (22, 23). Similarly, auto-
nomic system alterations, such as sympathetic
overactivity, are present in both depression and FM
(21). Finally, pro-inflammatory cytokines within
the CNS play a role in the pathophysiology of
mood disorders (and pain), and modulating these
cytokines via chronic antidepressant treatment con-
tribute to improve depression (and pain) (24). 
Several studies reported high frequency of mood
disorders in FM patients (25, 26) compared to con-
trols (27). Short-term clinical studies have shown
efficacy for antidepressants in the treatment of FM
(28). 
Abnormalities in central monoaminergic neuro-
transmission that are observed in depression might
play a role in FM pathophysiology because dys-
function of 5-HT– and NE-mediated descending
pain-inhibitory pathways is an important mecha-
nism related to the pain experienced by FM pa-
tients. Antidepressants that increase 5-HT and NE-
mediated neurotransmission are commonly used to
treat FM and other chronic pain conditions, partic-
ularly neuropathic pain. Inhibition of both the 5-HT
and NE reuptake transporters using tricyclic anti-
depressants (TCA) or SNRIs (serotonergic and no-
radrenergic reuptake inhibitors), seems more ef-
fective in treating pain, and FM, in general, than in-
hibition of either transporter alone using selective
serotonergic (SSRIs) or noradrenergic (NARIs) re-
uptake inhibitors (29-31). 
However, the efficacy of TCAs is counterbalanced
by side effects (32, 33), while the better-tolerated
SSRIs demonstrate less effectiveness in treating fi-
bromyalgia (34-37).
Antidepressants acting both on NE and 5HT in-
duce a contextual increase of the endogenous opi-
oid system response that raises the pain threshold
at the periacqueductal level and increases the gate
control of nociception at the spinal cord level (38).
Antidepressants usually produce a fast, direct anal-
gesic effect (on opioid, enkephalinergic, substance
P) that is independent of mood state; it first ap-
pears after a few hours and can be achieved with
low doses. 
After a longer period of 2-3 weeks, a more robust
analgesic effect develops when antidepressants
have a more profound influence on mood and anx-
iety, and the affective and cognitive components of
pain become regulated. This effect can only be pro-
duced with full doses that are easier to achieve with
the new generation of antidepressants, such as SS-
RIs and SNRIs (39, 40).
Concerning the use of antidepressants in fi-
bromyalgia, Perrot and colleagues (41) identified
forty-nine publications on the use of antidepres-
sants to treat painful rheumatologic conditions (in-
cluding 37 studies and 12 meta-analyses) that were
considered valid and used to develop the following
considerations: the analgesic effect is higher for
TCAs than SSRIs; clear evidence concerning dose-
response does not exist; the onset of action occurs
within a week; the route of administration is oral;
and side effects are more prevalent in TCAs than
SSRIs. Unfortunately, this review included studies
Table I - Summary of the controlled studies of dual reuptake inhibitors (SNRI).
Authors References Drug N. Pts Weeks Dose Outc. Results
Arnold, 2004 43 DUL vs PLA 207 12 120 FIQ DUL > PLA
Russell, 2008 44 DUL vs PLA 520 24 20-120 BPI DUL > PLA
PGI
Vitton et al., 2005 45 MIL vs PLA 125 4 200 PGI MIL > PLA
FIQ
Arnold, 2005 46 DUL > PLA 354 12 60-120 BPI DUL > PLA
VLF = venlafaxine; DUL = duloxetine; MIL = milnacipran; dose in mg/day; outc. = outcome measures: VAS = Visual Analog Scale; FIQ = Fibromyalgia Impact Questionnaire;
54 P. Sarzi-Puttini et al.
from 1966 to 2003 and did not consider new anti-
depressants such as SNRIs that are less effective
than TCAs but remarkably more tolerated, partic-
ularly in long-term treatment (42).
Antidepressants that act on both NE and 5HT, i.e.,
SNRIs (Serotonergic and Noradrenergic Reuptake
Inhibitors), are venlafaxine, duloxetine and mil-
nacipran (milnacipran is not marketed in Italy).
Only a few controlled studies are available to date;
these are summarized in Table I (43-46). All of
these controlled studies demonstrated a significant
superiority of the SNRI over placebo, and report-
ed few and mild side effects (more frequent nau-
sea, dry mouth and constipation in the first two
weeks of treatment) (47). 
Cyclobenzaprine, a tricyclic muscle relaxant, has
also proven to be moderately effective in FM pa-
tients at a dose of 10-40 mg/day (48). This has re-
cently been confirmed by a meta-analysis of five
randomised, placebo-controlled trials (49), which
showed that patients treated with cyclobenzaprine
were approximately three times as likely to report
symptom improvement, but there was a high
dropout rate and the duration of the studies was
short (49).
In our experience treating cancer pain with antide-
pressants, we have found that the impact of anti-
depressants on emotion and cognition is quite in-
teresting: after a month of treatment, especially
when brief psychotherapy is also included, patients
who have pain as well as maladaptive coping styles
(such as despair or hopelessness) begin to adopt
positive coping styles (such as fighting spirit). This
change is obtained by improving mood and re-
shaping beliefs about pain, both of which are ex-
tremely important in malignant pain diseases (50).
A final consideration involves the placebo effect in
pain treatment. 
In a medical model placebo is manly considered an
inert substance, and at present, it is well known
that the placebo effect on pain is mediated by an
opioid mechanism (51). 
In clinical practice, however, we consider that a
placebo effect is also an adjunct response to an ac-
tive drug: the individual expectation of a positive
response will increase the pharmacological action
of the drug, while a negative expectation will re-
duce the effectiveness of the therapy (nocebo ef-
fect). 
The placebo effect is highly related to the rela-
tionship between patient and physician (52), a re-
lationship that is also important in affecting phar-
macological treatments as well. 
Anticonvulsants/antiepileptic drugs
Antiepileptic drugs (i.e., gabapentin and prega-
balin) act at a number of sites that may be relevant
to pain. The precise mechanism of their analgesic
effect remains unclear, but it is thought that they
limit neuronal excitation and enhance inhibition
(53). The relevant sites of action include voltage-
gated ion channels (i.e., sodium and calcium chan-
nels), ligand-gated ion channels, excitatory recep-
tors for glutamate and Nmethyl-D-aspartate, the
inhibitory receptors for gamma-aminobutyric acid
(GABA) and glycine (54).
In preclinical pain models, gabapentin is a struc-
tural analogue of the neurotransmitter GABA; it ex-
erts robust analgesic and anti-allodynic effects in
syndromes that are secondary to sensitization of
pain responses but has minimal effects in models
of acute, transient pain (55). Taylor, et al. (56) sug-
gested that gabapentin did not appear to reduce
acute pain from injury, but appeared to be effective
in reducing abnormal hypersensitivity (allodynia
and hyperalgesia) induced by inflammatory re-
sponses or nerve injury. The antinociceptive effects
of gabapentin are hypothesized to be mediated by
modulation of calcium channels via 2 binding, mod-
ulation of transmission of GABA, and possibly oth-
er additional unidentified mechanisms.
Arnold, et al. (57) conducted a 12-week, random-
ized, double-blind study that was designed to com-
pare gabapentin (1,200-2,400 mg/day; n=75 pa-
tients) versus placebo (n=75 patients) for efficacy
and safety in treating pain associated with FM. Pa-
tients who were treated with gabapentin displayed
significantly greater improvements in the Brief
Pain Inventory (BPI) average pain interference
score, the Fibromyalgia Impact Questionnaire
(FIQ) total score, the Clinical Global Impression of
Severity, the Patient Global Impression of Im-
provement, the Medical Outcomes Study (MOS)
Sleep Problems Index, and the MOS Short Form 36
vitality score; but they did not show improvements
in the mean tender point pain threshold or the
Montgomery Asberg Depression Rating Scale.
Gabapentin was generally well tolerated by these
FM patients. 
Pregabalin is an α2-δ ligand that has analgesic, anx-
iolytic-like, and anticonvulsant activity in animal
models. Biochemical studies identified α2-δ (type
1) as the primary binding site for both pregabalin
and the related compound, gabapentin (57). Al-
pha2-delta is an auxiliary protein associated with
voltage-gated calcium channels. Potent binding of
pregabalin at the α2-δ site reduces calcium influx
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at nerve terminals (58) and, therefore, reduces the
release of several neurochemicals, including glu-
tamate, noradrenaline, and substance P (58, 59).
The reduced neurotransmitter release caused by
drug binding at the α2-δ site is presumed to ac-
count for the the analgesic, anticonvulsant, and
anxiolytic-like actions of pregabalin in animal
models. Reduction of neurotransmitter release from
neurons in the spinal cord and brain is also pro-
posed as the mechanism of action that may result
in clinical benefit for patients with FM. In an 8-
week, multicentre, double-blind, randomised,
placebo-controlled clinical trial, Crofford, et al.
(61) compared the effects of pregabalin (150, 300
and 450 mg/day) on pain, sleep, fatigue and health-
related quality of life in 529 FM patients, and found
that it was superior to placebo in reducing the
scores for pain, SF-MPQ, sleep index, fatigue, pa-
tient and clinician global impression of change,
and four of the eight SF-36 domains. The most fre-
quent adverse events were dizziness and somno-
lence. 
Arnold, et al. (62) conducted a study to assess
symptoms of anxiety and depression in a large co-
hort of FM patients to determine the impact of
these symptoms on pain during a course of prega-
balin treatment. The results indicated that anxiety
symptoms were more common than depressive
symptoms in this cohort, and that the pain treatment
effect of pregabalin did not depend on baseline
anxiety or depressive symptoms, which suggests
that pregabalin improves pain in patients with or
without these symptoms. Finally, much of the pain
reduction appears to be independent of improve-
ments in anxiety or mood symptoms.
In a multicenter, double-blind, placebo-controlled
trial, Mease, et al. (63) randomly assigned 748 FM
patients to receive placebo or pregabalin (300, 450,
or 600 mg/day, dosed twice daily) for 13 weeks.
The pregabalin groups showed statistically signifi-
cant improvements in mean pain score and in Pa-
tient Global Impression of Change (PGIC) com-
pared to the placebo group. Improvements in FIQ-
Total Score for the pregabalin groups were numer-
ically but not significantly greater than those for the
placebo group. Compared with placebo, all prega-
balin treatment groups showed statistically signifi-
cant improvement in assessments of sleep and in
patients’ impressions of their global improvement.
Dizziness and somnolence were the most fre-
quently reported adverse events. The study con-
cluded that pregabalin monotherapy provides clin-
ically meaningful benefit to patients with FM.
Other drugs
Serotonergic receptors have been implicated in pro-
cessing information and in the development of pain
in FM, and randomised, controlled trials have
found that tropisetron, a 5-hydroxytryptophan in-
termediate metabolite of L-tryptophan, is more ef-
fective than placebo (64, 65)
In a pilot study, Papadopoulos, et al. (66) found that
tropisetron might be effective in treating pain in FM
patients, but Koeppe, et al. (67) did not observe
any significant change in the intensity of habitual
pain following local injection of tropisetron in FM
patients who took part in a pre- and post-treatment,
double-blind study of pain perception and central
processing.
In an open trial of pindolol, a mixed serotonin (5-
HT)(1A) presynaptic autoreceptor/beta-adrenergic
receptor antagonist, at a dose of 7.5 mg/day (titrat-
ed to a maximum of 15 mg/day) for a total of 90
days in 20 female FM patients, Wood, et al. (68)
demonstrated a significant improvement in prima-
ry tender point counts (p<0.001), tender point
scores (p<0.001), and FIQ (p<0.005). The depres-
sion and anxiety scores did not significantly change
among the women who completed the study, and
the impact on cardiovascular parameters was clin-
ically insignificant (68). 
Despite the suggestion of relative growth hormone
(GH) deficiency in FM patients and reports of im-
provements after the administration of GH injec-
tions, the enthusiasm for this approach has been
dampened by the appearance of adverse effects,
the need for frequent injections, and its high cost
(69). 
Low doses of a β-blocker have been tried in se-
lected cases with prominent autonomic symptoms,
such as palpitations and orthostatic tachycardia;
however, the effects are not known (68).
Lidocaine hydrochloride injections, botulinum tox-
in injections, are sometimes offered to patients with
FM (1, 8, 70, 71).
CONCLUSIONS
The  success of the current treatments for FM is
still limited, and there is a need for the develop-
ment of new drugs that are targeted at the CNS, and
that undergo efficacy and  toxicity testing in long-
term, comparative trials involving large numbers of
patients. Recent data concerning polymorphisms
of the genes in the serotonergic and dopaminergic
systems may facilitate the development of a more
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SUMMARY
Pharmacological treatment has been gradually enriched by a variety of compounds; however, no single drug is capa-
ble of fully managing the constellation of fibromyalgia (FM) symptoms. Currently, it is not possible to draw definite
conclusions concerning the best pharmacological approach to managing FM because results of randomized clinical tri-
als present methodological limitations and therapeutic programs are too heterogeneous for adequate comparison. How-
ever, a variety of pharmacological treatments including antidepressants, nonsteroidal anti-inflammatory drugs
(NSAIDS), opioids, sedatives, muscle relaxants and antiepileptics have been used to treat FM with varying results. In
this review, we will evaluate those pharmacological therapies that have produced the most significant clinical results
in treating FM patients.
The nature of FM suggests that an individualized, multimodal approach that includes both pharmacologic and non-
pharmacologic therapies seems to be the most appropriate treatment strategy to date.
Key words - Pharmacologic approach, non-pharmacologic approach, opioids, antiepileptics, nonsteroidal anti-in-
flammatory drugs.
Parole chiave - Terapia farmacologica, terapia non-farmacologica, oppiodi, antiepilettici, anti-infiammatori non
steroidei.
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